MYB88 Antibody

What is MyD88 and why is it important in immunological research?

MyD88 (Myeloid differentiation primary response 88) functions as a critical adaptor molecule in the IL-1 signaling pathway involved in inflammatory responses induced by cytokines and LPS. It is expressed in a variety of tissues and serves as a key component in the innate and adaptive immune response . MyD88 associates with and recruits IRAK to the IL-1 receptor, playing an essential role in pathogen recognition and immune activation. Notably, targeted disruption of the MyD88 gene results in loss of cellular responses to IL-1 and IL-18, and MyD88-deficient mice lack responses to LPS, making it a crucial molecule for studying immune signaling pathways .

What are the molecular characteristics of MyD88 protein?

MyD88 has a calculated molecular weight of approximately 34 kDa but is typically observed at 29-35 kDa in Western blots, depending on the experimental conditions . The protein is derived from the human MyD88 gene spanning Met1-Pro296 (Accession # Q99836) . When detected via Western blot, MyD88 typically appears as a specific band at approximately 35 kDa under reducing conditions . The protein has wide tissue distribution and functions as an adaptor molecule for both Toll/IL-1R pathways and as a regulator for IL-18 receptor and the human Toll receptor family .

Which cell lines serve as appropriate positive controls for MyD88 antibody validation?

Several cell lines have been validated as positive controls for MyD88 antibody testing:

• Human cells: Raji human Burkitt's lymphoma cells, Jurkat human acute T cell leukemia cells, and HT-29 human colon adenocarcinoma cells

• Rodent cells: RAW 264.7 cells (mouse) and NR8383 cells (rat)

• Tissue samples: Mouse and rat liver tissues have demonstrated reliable MyD88 expression

These cellular models provide consistent MyD88 expression and are recommended for antibody validation experiments.

What is the subcellular localization of MyD88?

MyD88 is predominantly localized in the cytoplasm, consistent with its role as a cytoplasmic adaptor protein. Immunofluorescence studies using anti-MyD88 antibodies in Raji human Burkitt's lymphoma cells have confirmed this cytoplasmic localization pattern . When performing immunofluorescence staining, cells are typically counterstained with DAPI to visualize nuclei, which helps distinguish the cytoplasmic MyD88 signal from nuclear components .

How does MyD88 deficiency affect immune responses to vaccination?

Studies with MyD88 knockout mice (MyD88−/− mice) have revealed significant immunological defects following vaccination. When immunized with influenza virus-like particles (VLPs), these mice demonstrated:

• Deficient production of IgG2a/c isotype antibodies

• Impaired generation of splenic recall memory B cell responses

• Reduced antibody-secreting plasma cells in the bone marrow

• Decreased protective efficacy compared to wild-type mice

• Minimal boost response following secondary immunization

• Compromised T helper type 1 (Th1) isotype-switched antibody production

• Diminished IFN-γ-secreting T cell responses

These findings indicate that MyD88-mediated innate signaling is essential for effective generation of long-lived antibody-secreting plasma cells and protective immunity after vaccination .

What role does MyD88 play in NF-κB activation pathways?

MyD88 serves as a critical mediator in NF-κB activation through IL-1 receptor signaling. When IL-1 binds to its receptor, MyD88 is recruited to the receptor complex, which subsequently leads to IRAK recruitment and activation of downstream signaling cascades culminating in NF-κB activation . Research has demonstrated that dominant negative mutants of MyD88 attenuate IL-1R-mediated NF-κB activation, highlighting its essential role in this pathway . This mechanism is fundamental to inflammatory responses and represents a significant target for immunomodulatory therapeutics.

What are the implications of MyD88 mutations for disease development?

Evidence suggests that mutations in the MyD88 gene can lead to cancer development in both humans and mice, indicating a potential tumor suppressor role . MyD88-deficient mice exhibit pronounced immune deficiencies, including loss of cellular responses to IL-1 and IL-18, and absent LPS responses . These immunological defects predispose to infections and may alter inflammatory homeostasis. Understanding the relationship between MyD88 mutations and disease development provides valuable insights into potential therapeutic targets and the fundamental mechanisms of immune regulation.

What are the optimal conditions for MyD88 antibody use in Western blotting?

For optimal Western blot detection of MyD88:

It is critical to include appropriate positive controls and to optimize antibody concentration for each experimental system to achieve specific signal with minimal background .

How should researchers approach immunofluorescence staining for MyD88?

For successful immunofluorescence detection of MyD88:

• Immersion fix cells (e.g., Raji human Burkitt's lymphoma cell line)

• Apply primary anti-MyD88 antibody at an optimized concentration (e.g., 15 μg/mL)

• Incubate for appropriate duration (approximately 3 hours at room temperature)

• Use fluorophore-conjugated secondary antibodies matching the host species of primary antibody (e.g., NorthernLights™ 557-conjugated Anti-Goat IgG)

• Counterstain nuclei with DAPI for proper localization assessment

• Expect cytoplasmic staining pattern consistent with MyD88's subcellular distribution

Following specialized protocols for non-adherent cells is recommended for optimal staining results .

What considerations are important for flow cytometric analysis of MyD88?

Flow cytometric detection of MyD88 requires specific technical considerations:

• Cell fixation with paraformaldehyde to maintain cellular integrity

• Permeabilization with saponin to enable antibody access to intracellular MyD88

• Use of appropriate isotype control antibodies as negative controls

• Sequential staining with primary anti-MyD88 antibody followed by fluorophore-conjugated secondary antibody

• Careful gating strategy to differentiate positive signal from background and autofluorescence

• Histogram analysis comparing stained samples to isotype controls

This approach enables quantitative assessment of MyD88 expression across cell populations and under different experimental conditions.

What are common challenges in MyD88 detection and how can they be addressed?

For antibodies showing cross-reactivity between species (human/mouse), verify specificity using knockout or knockdown controls when available .

How can researchers validate the specificity of MyD88 antibodies?

Comprehensive validation approaches include:

• Using recombinant MyD88 protein as a positive control (1 ng is typically sufficient)

• Testing multiple cell lines with known MyD88 expression profiles (Raji, Jurkat, HT-29)

• Comparing detection with different antibodies targeting distinct MyD88 epitopes

• Performing blocking peptide competition assays to confirm binding specificity

• Using MyD88 knockout/knockdown samples as negative controls when available

• Verifying that observed molecular weight matches expected size (approximately 35 kDa)

• Confirming cytoplasmic localization pattern in imaging applications

These validation steps are essential for ensuring reliable and reproducible experimental results.

How can MyD88 antibodies contribute to vaccination research?

MyD88 antibodies enable critical analyses in vaccination studies:

• Monitoring MyD88-dependent immune activation following vaccination

• Comparing MyD88 expression and activation between wild-type and knockout models

• Correlating MyD88 signaling with antibody production and isotype switching

• Investigating memory B cell development and plasma cell generation

• Assessing the role of MyD88-dependent pathways in vaccine adjuvant effects

• Studying relationships between MyD88 signaling and protective immunity

Research has demonstrated that MyD88 plays an essential role in inducing B cells capable of generating protective immune responses following vaccination, particularly for the development of long-lived antibody-secreting plasma cells .

What approaches can researchers use to study MyD88's role in TLR signaling?

Multiple experimental strategies can illuminate MyD88's function in TLR pathways:

• Immunoprecipitation to identify protein-protein interactions in TLR signaling complexes

• Western blotting to analyze MyD88 recruitment to activated receptors and subsequent signaling

• Immunofluorescence to visualize subcellular MyD88 distribution during TLR activation

• Comparative studies between wild-type and MyD88-deficient models to distinguish MyD88-dependent and independent pathways

• Flow cytometry for quantitative assessment of cellular responses to TLR ligands

• Cytokine profiling to correlate MyD88 activation with downstream inflammatory responses

These approaches provide mechanistic insights into how MyD88 functions as a central adaptor in innate immune signaling cascades initiated by TLR activation.